Sunday, July 29, 2012

For Metastatic Melanoma, Should High-Dose Interleukin-2 Continue To Be The Treatment Of Choice?

Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV me ... http://p.ost.im/p/dJWqJr
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)